Previous 10 | Next 10 |
2024-03-28 13:11:15 ET More on Xeris Pharmaceuticals Xeris Biopharma (XERS) Q4 2023 Earnings Call Transcript Xeris Biopharma: Speculative Buy, Size Your Position Accordingly Xeris Biopharma Holdings Stock Is A Hold With Robust Performance Into 2024 Xeris Phar...
2024-03-28 08:00:00 ET Are stock splits back in style? About two years ago, a number of high-profile corporations made such moves after their shares rose to unwieldy levels. Now, Chipotle , one of the leading fast-casual restaurant chains, is on the verge of conducting a 50-for-1 stock ...
2024-03-26 14:36:26 ET Summary Regeneron Pharmaceuticals, Inc.'s Eylea HD reinforces its market dominance in treating wet AMD, competing effectively against biosimilars and Roche's Vabysmo. Libtayo's revenue growth is impressive, with expectations to become a blockbuster, enhancin...
2024-03-26 13:15:05 ET RBC Capital analyst issues BUY recommendation for REGN on March 26, 2024 10:01AM ET. The previous analyst recommendation was Buy. REGN was trading at $958.6051 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...
2024-03-26 13:15:05 ET Morgan Stanley analyst issues UNDERPERFORM recommendation for REGN on March 26, 2024 10:01AM ET. The previous analyst recommendation was Underperform. REGN was trading at $958.6051 at issue of the analyst recommendation. The overall analyst consens...
2024-03-25 10:29:37 ET More on Regeneron Pharmaceuticals Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript) Regeneron Pharmaceuticals, Inc. (REGN) Barclays 26th Annual Global Healthcare Conference (Transcript) Regeneron P...
TARRYTOWN, N.Y., March 25, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued Complete Response Letters (CRLs) for the Biologics License Application (BLA) for odronextamab in relapsed/refractory (R/R)...
2024-03-25 02:07:51 ET Summary Sanofi has underperformed the U.S. stock market lately but now offers one of the smartest growth-at-a-reasonable-price setups in Big Pharma. Sanofi is best known for its patented drug Dupixent and numerous vaccines manufactured for global use, which ...
2024-03-22 12:40:30 ET Intellia Therapeutics ( NASDAQ: NTLA ) is opting out of an agreement with Regeneron Pharmaceuticals ( NASDAQ: REGN ) to co-develop a factor IX gene editing therapy for hemophilia A and B, the biotechnology firm disclosed in a filing on Friday.... ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is one of today's top gainers. The company's shares have moved 0.41% on the day to $971.98. Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The compa...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
Amidst today's fast-paced and highly competitive business environment, it is crucial for investors and industry enthusiasts to conduct compreh...
TARRYTOWN, N.Y. and WASHINGTON, D.C., May 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Grace Sun, 16, of Lexington, Kentucky, won the $75,000 top award, the George D. Yancopoulos Innovator Award, named in honor of...
2024-05-16 07:15:00 ET Drugmakers outside the biosimilar or generic-medicine market must constantly innovate to be successful over long periods. Some are better at it than others. Eli Lilly (NYSE: LLY) and Regeneron Pharmaceuticals (NASDAQ: REGN) have historically been i...